We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.

Accept essential cookies
Accept all cookies
Sign in
Sign in
Companies → Chong Kun Dang Pharmaceutical Corp.
Save to list
Remove

Chong Kun Dang Pharmaceutical Corp.

South Korea, Seoul
Report a bug?
Claim ownership and edit
Description
Chong Kun Dang Pharmaceutical Corp. engages in the manufacturing, marketing, and sales of medicines in South Korea and internationally. It provides prescription drugs for anticancer, anti-hypertension, anti-hyperlipidemia, anti-diabetic, and immunosuppressant products; over-the-counter drugs for therapeutic benefits, supplements, and other preventive products; health supplements with preventive benefits, including prebiotics and vitamins with Omega-3; and consumer health products, such as red-ginseng healthy drink, hand sanitizer, and hair color medication, as well as insecticides. The company also exports its products. Chong Kun Dang Pharmaceutical Corp. was founded in 1941 and is headquartered in Seoul, South Korea.
Industries
SIC
Address:

8 Chungjeong-ro

Seodaemun-gu Seoul

Seoul

03742 Republic Of Korea

Website:
Revenue
Recent news:

Air Arabia Reports Record Q3 and Nine-Month 2025 Results

Air Arabia's record 2025 results show 16% profit growth, 14% passenger increase, and expansion to 212 routes with 88 aircraft in its fleet.

Source: IndexBox Nov 12, 2025

KRX - Delayed Quote - KRW
185750.KS
Candle
Line
1M
6M
1Y
5Y
Financial Statistics
Valuation Measures
Current
Quarterly
As of 03/22/2026
Market Cap: 1.17 T
Enterprise Value: 1.19 T
Trailing P/E: 15.17
Forward P/E: 12.57
PEG Ratio (5yr expected): N/A
Price/Sales (ttm): 0.69
Price/Book (mrq): 1.16
Enterprise Value/Revenue: 0.70
Enterprise Value/EBITDA: 8.94
Financial Highlights
Profitability and Income Statement
Profit Margin: 4.58%
Return on Assets (ttm): 3.09%
Return on Equity (ttm): 8.18%
Revenue (ttm): 1.69 T
Net Income Avi to Common (ttm): 77.51 B
Diluted EPS (ttm): N/A
Balance Sheet and Cash Flow
Total Cash (mrq): 346.50 B
Total Debt/Equity (mrq): 36.54%
Levered Free Cash Flow (ttm): -122.33 B
Company is likely to buy
Company is likely to sell
Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.